News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis lodges TGA application to market Bronchitol for CF in Australia
Pharmaxis today announced that it had submitted an application with the Therapeutic Goods Administration (TGA) to market Bronchitol in Australia for the treatment of cystic fibrosis.
Read full media release - pdf
Pharmaxis Announces Sustained Benefit with Bronchitol in Phase 3 Cystic Fibrosis Trial
Pharmaxis today announced significant headline results for the second six month dosing of its international Phase III trial of Bronchitol in people with cystic fibrosis.The lung function of patients treated with Bronchitol for a full twelve months improved from 6.5% at six months to 8.0% (p<0.001) at the end of twelve months treatment. In addition, the lung function of patients who were on placebo for the first six months of the study improved by 10.3% (p<0.001) when switched to Bronchitol.
Read full media release - pdf
FDA Advisory Committee Recommends Approval of Aridol
Pharmaxis today announced that an advisory committee of the U.S. Food and Drug Administration (FDA) has voted to recommend the approval of Aridol™ (mannitol bronchial challenge test) for use as a bronchial test to assess bronchial hyperresponsiveness to aid in diagnosing patients who have symptoms of asthma or symptoms that are suggestive of asthma.
Read full media release - pdf